Emend contains the active ingredient fosaprepitant dimeglumine, which is a prodrug of aprepitant, a substance P/neurokinin-1 (NK) receptor antagonist. It comes in a sterile, lyophilized form intended for intravenous infusion. Each vial contains 245.3 mg of fosaprepitant dimeglumine, equivalent to 150 mg of fosaprepitant free acid. Key inactive ingredients include edetate disodium, lactose anhydrous, and polysorbate 80.
How should I use this medication?
This medication is for injection into a vein. It is given in a hospital or clinic setting. Talk to your care team about the use of this medication in children. While this medication may be prescribed for children as young as 6 months for selected conditions, precautions do apply.
Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once. NOTE: This medicine is only for you. Do not share this medicine with others.
What if I miss a dose?
This does not apply.
Where should I keep my medication?
This medication is given in a hospital or clinic and will not be stored at home.
NOTE: This sheet is a summary. It may not cover all possible information. If you have questions about this medicine, talk to your doctor, pharmacist, or health care provider.
What side effects may I notice from receiving this medication?
Side effects that you should report to your care team as soon as possible: -Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome): -Diarrhea -Fatigue -Pain, redness, or irritation at injection site -Pain, tingling, or numbness in the hands or feet -Unusual weakness or fatigue -Upset stomach
This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What should I tell my care team before I take this medication?
They need to know if you have any of these conditions: -Liver disease -An unusual or allergic reaction to fosaprepitant, aprepitant, medications, foods, dyes, or preservatives -Pregnant or trying to get pregnant -Breast-feeding
What may interact with this medication?
Do not take this medication with any of these: -Cisapride -Flibanserin -Lomitapide -Pimozide This medication may also interact with the following: -Diltiazem -Estrogen or progestin hormones -Medications for fungal infections, such as ketoconazole and itraconazole -Medications for HIV -Medications for seizures or to control epilepsy, such as carbamazepine or phenytoin -Medications used for sleep or anxiety disorders, such as alprazolam, diazepam, or midazolam -Nefazodone -Paroxetine -Ranolazine -Rifampin -Some antibiotics, such as clarithromycin, erythromycin, troleandomycin -Some chemotherapy medications, such as etoposide, ifosfamide, vinblastine, vincristine -Steroid medications, such as dexamethasone or methylprednisolone -Tolbutamide -Warfarin
This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.
What should I watch for while using this medication?
Do not take this medication if you already have nausea and vomiting. Ask your care team what to do if you already have nausea. Estrogen and/or progestin hormones may not work as well while you are taking this medication. A barrier contraceptive, such as a condom or diaphragm, is recommended during treatment and for up to 1 month after your last dose of fosaprepitant if you are using these hormones for contraception. Talk to your care team about other forms of contraception. This medication should not be used continuously for a long time. Visit your care team for regular check-ups. This medication may change your liver function blood test results.
Source: This information is sourced from Elsevier Inc.
The reviews, ratings, comments, and opinions expressed on this platform are solely those of the individual medical professionals who posted them and do not reflect the views or positions of Sermo, Inc. Sermo does not endorse, verify, or validate the content of individual reviews. The information provided is user-generated and reflects personal clinical experiences, which may not be complete, accurate, or applicable to your specific health needs. It is not intended as medical advice.
Prescription medications affect individuals differently, and what works for one person may not work for another. Always consult your doctor, pharmacist, or other qualified healthcare provider to ensure the information displayed applies to your personal circumstances. Only a licensed healthcare provider can advise you on what is safe and effective for you.
Keep all medications out of the reach of children, never share your medicine with others, and use each medication only as prescribed. Your reliance on any information provided on this platform is at your own risk.
Sermo Drug Ratings, and all information provided on this website, may not be used in combination with any artificial intelligence tool (including to train an algorithm, test, process, analyze, generate output and/or develop any form of artificial intelligence tool).
Visitors to the online patient-facing website at Sermo.com (“Sermo Drug Ratings”) are Authorized Users of the website, which contains data owned by a third-party provider, Elsevier, Inc. Accordingly, by visiting Sermo Drug Ratings, Authorized User acknowledges that the website includes Elsevier owned data that Sermo licenses pursuant to a separate usage and Data agreement (the “Agreements”). Authorized User further acknowledges that Sermo is a third-party beneficiary of the Agreements and Authorized User’s use of the website hereby binds them to the terms of the Agreements; provided, however, that Elsevier shall have no obligations or liability to an Authorized User whatsoever pursuant to the terms of the Agreements.